PURPOSE: Variability exists in the adjuvant treatment for endometrial cancer (EC) based on surgical pathology and institutional preference. The radiosensitivity index (RSI) is a previously validated multigene expression index that estimates tumor radiosensitivity. We evaluate RSI as a genomic predictor for pelvic failure (PF) in EC patients treated with adjuvant radiation therapy (RT). METHODS AND MATERIALS: Using our institutional tissue biorepository, we identified EC patients treated between January 1999 and April 2011 with primarily endometrioid histology (n = 176; 86%) who received various adjuvant therapies. The RSI 10-gene signature was calculated for each sample using the previously published algorithm. Radiophenotype was determined using the previously identified cutpoint where RSI ≥ 0.375 denotes radioresistance (RR) and RSI < 0.375 describes radiosensitivity. RESULTS: A total of 204 patients were identified, of which 83 (41%) were treated with adjuvant RT. Median follow-up was 38.5 months. All patients underwent hysterectomy with bilateral salpingo-oophorectomy with the majority undergoing lymph node dissection (n = 181; 88%). In patients treated with radiation, RR tumors were more likely to experience PF (3-year pelvic control 84% vs 100%; P = .02) with worse PF-free survival (PFFS) (3-year PFFS 65% vs 89%; P = .04). Furthermore, in the patients who did not receive RT, there was no difference in PF (P = .87) or PFFS (P = .57) between the RR/radiosensitive tumors. On multivariable analysis, factors that continued to predict for PF included the RR phenotype (hazard ratio [HR], 12.2; P = .003), lymph node involvement (HR, 4.4; P = .02), and serosal or adnexal involvement (HR, 5.3; P = .01). CONCLUSIONS: On multivariable analysis, RSI was found to be a significant predictor of PF in patients treated with adjuvant RT. We propose using RSI to predict which patients are at higher risk for failing in the pelvis and may be candidates for treatment escalation in the adjuvant setting.
PURPOSE: Variability exists in the adjuvant treatment for endometrial cancer (EC) based on surgical pathology and institutional preference. The radiosensitivity index (RSI) is a previously validated multigene expression index that estimates tumor radiosensitivity. We evaluate RSI as a genomic predictor for pelvic failure (PF) in ECpatients treated with adjuvant radiation therapy (RT). METHODS AND MATERIALS: Using our institutional tissue biorepository, we identified ECpatients treated between January 1999 and April 2011 with primarily endometrioid histology (n = 176; 86%) who received various adjuvant therapies. The RSI 10-gene signature was calculated for each sample using the previously published algorithm. Radiophenotype was determined using the previously identified cutpoint where RSI ≥ 0.375 denotes radioresistance (RR) and RSI < 0.375 describes radiosensitivity. RESULTS: A total of 204 patients were identified, of which 83 (41%) were treated with adjuvant RT. Median follow-up was 38.5 months. All patients underwent hysterectomy with bilateral salpingo-oophorectomy with the majority undergoing lymph node dissection (n = 181; 88%). In patients treated with radiation, RR tumors were more likely to experience PF (3-year pelvic control 84% vs 100%; P = .02) with worse PF-free survival (PFFS) (3-year PFFS 65% vs 89%; P = .04). Furthermore, in the patients who did not receive RT, there was no difference in PF (P = .87) or PFFS (P = .57) between the RR/radiosensitive tumors. On multivariable analysis, factors that continued to predict for PF included the RR phenotype (hazard ratio [HR], 12.2; P = .003), lymph node involvement (HR, 4.4; P = .02), and serosal or adnexal involvement (HR, 5.3; P = .01). CONCLUSIONS: On multivariable analysis, RSI was found to be a significant predictor of PF in patients treated with adjuvant RT. We propose using RSI to predict which patients are at higher risk for failing in the pelvis and may be candidates for treatment escalation in the adjuvant setting.
Authors: Elena B Pereira; Brian De; Valentin Kolev; Konstantin Zakashansky; Sheryl Green; Peter Dottino; Vishal Gupta Journal: Int J Gynecol Cancer Date: 2016-02 Impact factor: 3.437
Authors: Carien L Creutzberg; Remi A Nout; Marnix L M Lybeert; Carla C Wárlám-Rodenhuis; Jan J Jobsen; Jan-Willem M Mens; Ludy C H W Lutgens; Elisabeth Pras; Lonneke V van de Poll-Franse; Wim L J van Putten Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-02 Impact factor: 7.038
Authors: Sarah E Ferguson; Tony Panzarella; Susie Lau; Lilian T Gien; Vanessa Samouëlian; Christopher Giede; Helen Steed; Tien Le; Ben Renkosinski; Marcus Q Bernardini Journal: Gynecol Oncol Date: 2018-04-19 Impact factor: 5.482
Authors: Javier F Torres-Roca; Steven Eschrich; Haiyan Zhao; Gregory Bloom; Jimmy Sung; Susan McCarthy; Alan B Cantor; Anna Scuto; Changgong Li; Suming Zhang; Richard Jove; Timothy Yeatman Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701
Authors: Steven A Eschrich; William J Fulp; Yudi Pawitan; John A Foekens; Marcel Smid; John W M Martens; Michelle Echevarria; Vidya Kamath; Ji-Hyun Lee; Eleanor E Harris; Jonas Bergh; Javier F Torres-Roca Journal: Clin Cancer Res Date: 2012-07-25 Impact factor: 12.531
Authors: Tobin Strom; Sarah E Hoffe; William Fulp; Jessica Frakes; Domenico Coppola; Gregory M Springett; Mokenge P Malafa; Cynthia L Harris; Steven A Eschrich; Javier F Torres-Roca; Ravi Shridhar Journal: Radiother Oncol Date: 2015-07-30 Impact factor: 6.280
Authors: Stephanie M de Boer; Remi A Nout; Ina M Jürgenliemk-Schulz; Jan J Jobsen; Ludy C H W Lutgens; Elzbieta M van der Steen-Banasik; Jan Willem M Mens; Annerie Slot; Marika C Stenfert Kroese; Simone Oerlemans; Hein Putter; Karen W Verhoeven-Adema; Hans W Nijman; Carien L Creutzberg Journal: Int J Radiat Oncol Biol Phys Date: 2015-08-18 Impact factor: 7.038
Authors: Kamran A Ahmed; Jacob G Scott; John A Arrington; Arash O Naghavi; G Daniel Grass; Bradford A Perez; Jimmy J Caudell; Anders E Berglund; Eric A Welsh; Steven A Eschrich; Thomas J Dilling; Javier F Torres-Roca Journal: J Thorac Oncol Date: 2018-05-05 Impact factor: 20.121
Authors: Stephanie M de Boer; Melanie E Powell; Linda Mileshkin; Dionyssios Katsaros; Paul Bessette; Christine Haie-Meder; Petronella B Ottevanger; Jonathan A Ledermann; Pearly Khaw; Alessandro Colombo; Anthony Fyles; Marie-Helene Baron; Ina M Jürgenliemk-Schulz; Henry C Kitchener; Hans W Nijman; Godfrey Wilson; Susan Brooks; Silvestro Carinelli; Diane Provencher; Chantal Hanzen; Ludy C H W Lutgens; Vincent T H B M Smit; Naveena Singh; Viet Do; Romerai D'Amico; Remi A Nout; Amanda Feeney; Karen W Verhoeven-Adema; Hein Putter; Carien L Creutzberg Journal: Lancet Oncol Date: 2018-02-12 Impact factor: 41.316
Authors: Philip Sutera; Matthew P Deek; Kim Van der Eecken; Alexander W Wyatt; Amar U Kishan; Jason K Molitoris; Matthew J Ferris; M Minhaj Siddiqui; Zaker Rana; Mark V Mishra; Young Kwok; Elai Davicioni; Daniel E Spratt; Piet Ost; Felix Y Feng; Phuoc T Tran Journal: Prostate Date: 2022-08 Impact factor: 4.012
Authors: Jeffrey C Buchsbaum; Michael G Espey; Ceferino Obcemea; Jacek Capala; Mansoor Ahmed; Pataje G Prasanna; Bhadrasain Vikram; Julie A Hong; Beverly Teicher; Molykutty J Aryankalayil; Michelle A Bylicky; C Norman Coleman Journal: J Clin Oncol Date: 2022-03-04 Impact factor: 50.717
Authors: Casey L Liveringhouse; Iman R Washington; Roberto Diaz; Rachel B Jimenez; Eleanor E Harris; Rachel Rabinovitch; Wendy A Woodward; Javier F Torres-Roca; Kamran A Ahmed Journal: Adv Radiat Oncol Date: 2021-05-28